Insulet (NASDAQ:PODD) Announces Earnings Results

Insulet (NASDAQ:PODD) posted its quarterly earnings results on Wednesday. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.59 by $0.40, FiscalAI reports. The company had revenue of $842.00 million for the quarter, compared to analyst estimates of $832.63 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%. Insulet’s revenue for the quarter was up 19.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.24 EPS.

Here are the key takeaways from Insulet’s conference call:

• Third-quarter revenue rose 19.6% in constant currency to $842 million, supported by more than 20% growth in the global customer base. Adjusted operating margin expanded 490 basis points, and adjusted EPS increased 60% year over year.
• Insulet raised its 2026 outlook to the high end of its prior range, expecting 21%–22% constant-currency revenue growth and more than 30% adjusted EPS growth. It also expects approximately 150 basis points of adjusted operating margin expansion.
• Management expects 2027 revenue growth to be modestly below its prior mid-teens framework, with U.S. growth toward the lower end of its earlier range and international growth moderating meaningfully. The company cited tougher comparisons, less international price-mix benefit, new competition, and limited near-term contributions from launches.
• Insulet reported modest improvement in type 2 customer retention after changes to sampling, onboarding, sales incentives, and customer support. Its Omnipod Discover platform has been adopted by more than 35,000 users and 5,000 clinicians, though management said the impact of these efforts will build over time.
• The board approved a $1 billion increase to the share repurchase authorization, with $400 million planned for repurchases in the fourth quarter using cash on hand.

Insulet Stock Up 6.5%

Shares of NASDAQ:PODD traded up $10.03 on Wednesday, hitting $164.89. 1,782,472 shares of the company’s stock were exchanged, compared to its average volume of 1,393,307. Insulet has a 1-year low of $126.40 and a 1-year high of $354.88. The company has a market capitalization of $11.44 billion, a PE ratio of 30.82, a P/E/G ratio of 1.21 and a beta of 1.06. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. The firm’s 50-day moving average is $141.21 and its 200 day moving average is $178.61.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q3 adjusted earnings were $1.99 per share, beating the $1.59 consensus estimate; revenue grew 19.2% year over year to $842 million, also ahead of expectations. Insulet Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Insulet authorized a $1 billion share buyback, which could support demand for its shares. The company also raised its 2026 outlook, according to coverage of its results. Insulet announces a $1 billion share buyback
• Neutral Sentiment: Reports indicate the company maintained its 2026 EPS outlook, even as it raised its broader outlook. Insulet Q3 earnings, revenue rise; 2026 EPS outlook maintained
• Negative Sentiment: CEO commentary pointed to slower growth in 2027 and potential loss of Omnipod market share as rivals compete more aggressively. This could temper expectations despite the strong quarter. Insulet CEO sees slower growth in 2027 and competition for Omnipod

Analyst Ratings Changes

PODD has been the topic of several analyst reports. Benchmark reduced their target price on shares of Insulet from $250.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Insulet in a report on Monday, September 21st. Barclays raised shares of Insulet to a “hold” rating in a research report on Wednesday, October 7th. Leerink Partners downgraded shares of Insulet from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $247.00 to $145.00 in a research report on Thursday, August 6th. Finally, BTIG Research lowered shares of Insulet from a “buy” rating to a “neutral” rating in a report on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $186.68.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.